November 5, 2012 /PRNewswire/ --
Syneron Medical Ltd. (NASDAQ: ELOS),
http://www.syneron.com, the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in
London, just prior to the opening of the
BODY Conference and Exhibition (
http://www.bodyconference.co.uk), which took place in
November 3-4, 2012 and for which Syneron was the main sponsor.
To view the Multimedia News Release, please click:
At the press conference, Syneron's Founder and Chairman of the Board,
, Ph.D., and Syneron's Chief Executive Officer,
provided an overview of Syneron's innovative technologies addressing the body shaping market as well as data on the market size and trends. The technologies presented included the Company's market leading UltraShape
product lines. UltraShape was the first minimally invasive fat destructive system and features proprietary focused ultrasound technology. VelaShape, with an installed base of more than 7,000 systems worldwide, was the first non-invasive body shaping device and features Syneron's proprietary elōs technology. Together, these complementary product lines are the basis for Syneron's global leadership position and state-of-the-art know-how with regards to non-invasive body shaping treatments.
As the leader with over 10 years of experience in treating both superficial fat and cellulite, Syneron has accumulated vast clinical information to safely and effectively meet consumer needs and desires. During the press conference, Syneron reviewed its on-going multi-center clinical trials and research activities focused on body shaping technologies. These investments highlight the Company's commitment to "Science - Results - Trust" in its efforts to develop the technology behind all of its products.